Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated. Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythmâs MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the communityâs understanding of the ongoing impact and burden of disease on patients and caregivers. Source
No articles found.
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Otonomy is a biopharmaceutical company dedicated to the development of innovative ...
Otonomy is a biopharmaceutical company dedicate...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
Join the National Investor Network and get the latest information with your interests in mind.